LIPO GANTRISIN
LOE ApproachingNDAORALEMULSION
Approved
Dec 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIPO GANTRISIN is a Roche-sponsored oral emulsion small molecule approved in 1953 with an unknown mechanism of action and indication profile. The drug's specific therapeutic class and clinical indications are not disclosed in available data.
LOE Approaching
With LOE approaching and no current Part D spending data, this product is in defensive/wind-down phase with likely shrinking commercial infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job postings and LOE approaching, career opportunities on LIPO GANTRISIN are minimal and focused on managed decline. Professionals should expect role transitions toward portfolio rationalization and generic-era supply chain management.
Brand Manager (Legacy Products)Commercial Operations
Worked on LIPO GANTRISIN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.